Clinical Trial Update: A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating an immune suppression treatment for people with sickle cell disease or beta-thalassemia undergoing allogeneic hemato…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Sickle Cell Disease

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sickle Cell Disease, Thalassemia, Beta | Phase 2 | Status: RECRUITING